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Abstract
Objectives—Driving under the influence of prescription and over-the-counter medication is a 
growing public health concern. A systematic review of the literature was performed to investigate 
which specific medications were associated with increased risk of motor vehicle collision (MVC).
Methods—The a priori inclusion criteria were: 1) studies published from English-language 
sources on or after January 1, 1960, 2) licensed drivers 15 years of age and older, 3) peer-reviewed 
publications, master's theses, doctoral dissertations, and conference papers, 4) studies limited to 
randomized control trials, cohort studies, case-control studies, or case-control type studies 5) 
outcome measure reported for at least one specific medication, 6) outcome measure reported as the 
odds or risk of a motor vehicle collision. Fourteen databases were examined along with hand-
searching. Independent, dual selection of studies and data abstraction was performed.
Results—Fifty-three medications were investigated by 27 studies included in the review. Fifteen 
(28.3%) were associated with an increased risk of MVC. These included Buprenorphine, Codeine, 
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Dihydrocodeine, Methadone, Tramadol, Levocitirizine, Diazepam, Flunitrazepam, Flurazepam, 
Lorazepam, Temazepam, Triazolam, Carisoprodol, Zolpidem, and Zopiclone.
Conclusions—Several medications were associated with an increased risk of MVC and 
decreased driving ability. The associations between specific medication use and the increased risk 
of MVC and/or affected driving ability are complex. Future research opportunities are plentiful 
and worthy of such investigation.
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1. INTRODUCTION
While the number of motor vehicle collisions (MVC) and subsequent fatalities has steadily 
declined over the past decade among many high-income countries, MVC still remains one of 
the leading causes of mortality not just globally, but also within the United States (U.S.). 1-3 
In 2010, this equated to approximately one death per collision every fifteen minutes in the 
U.S.3 Besides the inherent risks to morbidity and mortality, MVCs are estimated to cost the 
U.S. over $300 billion dollars per year.3
While driving under the influence of alcohol is a well-documented area of study, driving 
under the influence of drugs (DUID) is also an emerging public health and traffic safety 
concern.4-7 Driving under the influence of drugs entails the use of illicit drugs, i.e. drugs that 
are obtained illegally and with no real medical benefit, such as cocaine and 
methamphetamine. Driving under the influence of drugs can also entail the use of licit 
substances, such as common prescription or over-the-counter medications, whose effects 
impair the driver's ability to safely operate a motor vehicle from one destination to another. 
However, it's important to realize that while licit drugs can be obtained illegally, abused, or 
misused, the intent of use by the driver is often difficult to determine. In 2009, 
approximately 28% of all fatally injured U.S. drivers that were tested for either illicit or licit 
drugs tested positive for one or more of these substances.8 In addition, recent research 
suggests that DUID is increasing nationally.9
Due to the complexity of DUID, the primary focus of this paper pertains to the association 
between licit drug use and MVC. However, one of the fundamental challenges to studying 
the effects of licit drugs on driving ability is that the relationship is not always as apparent 
when compared to alcohol.8 For example, some drugs may not noticeably impair the skills 
(cognition, psychomotor function, physical ability) necessary to operate a motor 
vehicle.10-13 Drugs that are perceived to affect the central nervous system may exhibit 
different effects among individuals; this may be attributed to the pharmacokinetic or 
pharmacodynamic properties of the drug,14 the drug's half-life,15 interactions with other 
consumed drugs,16 tolerance, 17 drug elimination rate,16 dosage,15 route of administration,16 
solubility,18 intestinal pH,18 current health status of the individual,16 genetics,19 etc. It may 
also be difficult to partition out the effects of the licit drug and the medical condition for 
which it was taken to remedy.16 For example, several medical conditions have been 
associated with an increased risk of MVC. These include, but are not necessarily limited to, 
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sleep apnea, 20 dementia, 21 arthritis, 22 diabetes, 23 epilepsy, 23 anxiety, 24 depression, 24 
and Parkinson's disease.25
Numerous reviews and meta-analyses have investigated the association between licit drug 
use and MVC and/or driving ability. These reviews have focused predominately on 
opioids,26-34 benzodiazepines,29,31,35-38 antihistamines,39,40 psychoactive drugs,41-45 
antidepressants,36,46-49 hypnotics,43,50 anxiolytics,51,52 and sleep medications.53-56 Some 
reviews have also examined multiple drug categories.57-60 However, the majority of these 
studies have reviewed or analyzed licit drugs in broad groups.27,29-31,36,37,42,48 There is the 
potential that if the drugs within these groups were reviewed individually, the outcome 
measures of interest may be varied as some drugs may be more or less driver-impairing than 
others. Therefore, the purpose of this study was to perform a systematic review of the 
literature to investigate which specific medications, including typical prescription or over-
the-counter drugs, may be associated with an increased risk or odds of MVC and/or driving 
ability among licensed drivers 15 years of age and older.
2. MATERIALS AND METHODS
2.1 Study eligibility
The inclusion criteria for studies, which was defined a priori, were as follows: 1) English-
language studies published on or after January 1, 1960, 2) licensed drivers 15 years of age 
and older, 3) studies published in a peer-reviewed journal or non-published (i.e. “grey 
literature”), which included master's theses, doctoral dissertations, and conference papers, 4) 
studies limited to randomized control trials, cohort studies, case-control studies, or case-
control types of studies , i.e. case cross-over, case-time series, etc. 5) outcome measure 
reported for at least one specific medication, 6) outcome measure reported as the odds or 
risk of a motor vehicle collision or some affected aspect of driving ability during an on-road 
assessment or driving simulation (e.g. brake reaction time, weaving, standard deviation of 
lateral position, etc.). If the study reported outcome measures for both specific medications 
and illicit drugs or specific medications combined with alcohol, only outcome measures for 
specific medications alone were reported. A ‘medication’ was defined as a substance either 
available by prescription or over-the-counter to remedy a medical condition. Therefore, 
caffeine, nicotine, vitamins, and nutraceuticals were excluded. If the medication usage was 
combined with a medical procedure, then the study was excluded to avoid bias. While 
marijuana has been legalized for medicinal purposes in several states, it was not considered a 
medication in this analysis as it is still defined as an illegal substance by federal law. 
Because of the vast difference in the fidelity of driving simulators, a driving simulator must 
have consisted of a screen, pedals, and steering wheel. If the study did not specify the 
components of the simulator, an attempt was made to search the make and model of the 
simulator noted in the study to see if it was comprised of these constituents. The search date 
of January 1, 1960 was arbitrarily chosen as no DUID studies existed or were published 
prior to this time. Because of the complexity of the initial study question, it was decided 
post-hoc to only present the studies whose outcomes reported the association between a 
specific medication and the odds or risk of a motor vehicle collision.
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Studies were acquired from the following fourteen databases: 1) Medline (within EBSCO 
host), 2) PubMed, 3) Scopus, 4) International Pharmaceutical Abstracts (IPA), 5) Cochrane 
Central Register of Controlled Trials (CENTRAL), 6) CINAHL (within EBSCO host), 7) 
AgeLine, 8) Web of Science (WOS), 9) PsychInfo, 10) Transportation Research Information 
Services (TRID), 11) Academic Search Complete, 12) EconLit 13) SafetyLit, and 14) 
ProQuest Dissertations and Theses (ProQuest). All searches were performed by TMR with 
the assistance of a Health Sciences Librarian from West Virginia University. The last search 
was performed in June 2014. All searches were conducted using Medical Subject Headings 
(MESH) terminology. Each search contained the phrases, “drug”, “medication”, “traffic 
collision”, and “motor vehicle”. An example search strategy (ProQuest) is included in 
Appendix A.1. In addition to the fourteen databases, studies from TMR's personal library 
were also reviewed for eligibility. Hand searches from the reference lists of included studies 
were also examined. Government websites, such as the National Highway Traffic Safety 
Administration, were also searched for relevant government-performed studies.
2.3 Selection of studies
All included studies were independently selected by TMR and BR. Any discrepancies 
regarding the inclusion of studies were resolved through discussion. If a consensus could not 
be reached, MZ acted as the arbitrator. All studies, whether included or excluded in the 
review, were stored in EndNote, version X5, along with reasons for including or excluding 
the study.
2.4 Data abstraction
A codebook was developed by TMR in Microsoft Excel 2007. The codebook included 
variables regarding study characteristics (i.e. study design, year when published, etc.), study 
population (i.e. country of origin, ages/sex of participants, etc.), medications investigated, 
outcome measures, and study quality. All studies were coded by TMR and CP independent 
of one another. After coding was completed, both authors met to compare the entries for 
accuracy and/or precision. Any discrepancies were resolved through discussion. If 
disagreements could not be rectified, MZ acted as the arbitrator.
2.5 Study quality
The included studies were evaluated for quality by TMR and CP independent of one another. 
An abbreviated version of the checklist for measuring study quality designed by Downs and 
Black was used to score the studies for quality.61 The original checklist designed by Downs 
and Black, which has been deemed both valid and reliable, is a 27 question, qualitative 
check-list to evaluate a study for internal and external validity, quality of reporting, and 
power; for every positive attribute/response, a study receives one point.61 At the end of 
assessment, the points are tallied; the more points a study earns, the higher the study's 
quality.61 Since not all questions in the Downs and Black scale were applicable to the 
review, the abbreviated checklist contained 5 measures of quality (i.e. a total of 5 possible 
points). It was determined a priori that if a study had less than 3 points, it would not be 
included in the review. After all coding and quality assessments were completed, the authors 
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met to compare their entries for accuracy and/or precision. Any discrepancies were resolved 
through discussion. If disagreements could not be reached, MZ acted as the arbitrator. No 
studies that met the eligibility criteria were excluded based on quality.
2.6 Data synthesis
All studies were synthesized qualitatively. No meta-analysis was performed given the a 
priori assumption that excessive statistical and/or methodological heterogeneity would be 
observed.62 However, the overall odds or risk ratio for each medication and outcome was 
presented graphically and included the point estimate and corresponding 95% confidence 
intervals. Post hoc, it was realized that some included studies only presented crude 
estimates, 63-82 while others adjusted their outcome measures for various potential 
confounders such as age, gender, miles driven, day of the week, etc.83-89 For those studies 
that presented adjusted estimates or did not include 95% confidence intervals for crude 
estimates, 83-89 then the adjusted point estimates and 95% confidence intervals for the 
population were reported. If a study's point estimate was greater than 1, this indicated that 
there was excess risk of collision; a point estimate less than 1 indicated that the medication 
use was associated with a decreased risk of collision (i.e. it was protective against MVC). 




The search processes for the selection of studies, as well as reasons for excluding studies, 
are presented in Figure 1. Of the 6,516 records obtained, 208 studies met the original study 
question. Of these 208 studies, 27 pertained to the association of specific medications and 
the odds or risk of motor vehicle collision, while the others pertained to the association of 
specific medications and affected driving ability determined through the use of driving 
simulators (n=90) or actual driving assessments (n=91).
The characteristics of the 27 studies included in this review are presented in Table 1. 63-89 
The included studies spanned from 1992-2013. Of these studies, eight (29.6%) were 
conducted in Norway,69,70,72,73,75,77,79,82 six (22.2%) in the United States,63,64,81,83-85 five 
(18.5%) from Canada,65,66,86-88 three (11.1%) from England,71,74,76 three (11.1%) from 
France,67,78,80 one (3.7%) from the Netherlands,68 and one (3.7%) from Taiwan.89 Eleven 
(40.7%) of these studies were cohort designs, while the rest consisted of case-control or 
variations of a case-control design. Only one study was limited to females.63 Nine (33.3%) 
of the studies were limited to older adult drivers typically 60 years of age and older, nine 
(33.3%) included drivers aged approximately 18-70 years, and the remaining nine (33.3%) 
covered all licensed drivers from the country of origin. Three studies (11.1%) were doctoral 
dissertations, 63,66,81 one study (3.7%) was a conference paper, 68 and the remaining 23 
studies (85.2%) were published in peer-reviewed journals. Among these studies, 53 specific 
medications were evaluated. Diazepam, Zolpidem, Zopiclone, and Insulin were the most 
commonly studied medications. With respect to study quality, 23 of the 27 studies (85.2%) 
received a score of 5 (Table 1). The studies that were scored 4 out of 5 typically did not 
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explain their statistical methodology in sufficient detail, i.e., did not mention or explain what 
types of regression they utilized to obtain study outcome measurements.65,67,68
3.2 Study outcomes
The medications that were investigated by the studies included in this review are presented 
by drug category in Figures 2-9. The drug categories consisted of analgesics, 
anticonvulsants, antidepressants, antihistamines, antihyperglycemics, benzodiazepines, and 
sleep-enhancing medications; if a drug could not be categorized into any of these groups, it 
classified as ‘Other Medications’. Studies were adjusted by the original study authors for age 
and gender,83 age, sex, gender, and annual mileage,84 age, sex, gender, and days driven per 
week,85 and age, gender, residence in the country, previous injurious MVC, chronic disease 
score, exposure to antidepressants, anti-epileptics, benzodiazepines, antipsychotics, anti-
migraine, muscle relaxants, and narcotic analgesics.86 Another study was adjusted for 
cardiac or stroke events within the past year as well as the following drug classes in the 
previous 60 days: antidepressants, anti-epileptics, benzodiazepines, antipsychotics, anti-
migraine, narcotic analgesics, muscle relaxants.87 Another study was adjusted for age, 
gender, previous MVC, and place of residence,88 while another was adjusted for 
concomitant use of the following medications: Zolpidem, Zopiclone, long and short acting 
benzodiazepines, antihistamines, anticonvulsants, antidepressants, other sedatives/hypnotics, 
other psychoactive drugs, muscle relaxants, and opioid analgesics.89
3.2.1 Analgesics—Among the included studies, the associations between seven analgesic 
medications and the odds or risk of MVC were investigated (Figure 2). These medications 
included Aspirin83 Buprenorphine,80 Codeine,68,72,74 Dihydrocodeine,74 Methadone,79,80 
Morphine,74 and Tramadol.72,74 As shown in Figure 2, those taking Aspirin83 and 
Morphine74 did not experience a statistically significant increase in MVC; contrarily, those 
taking Buprenorphine,80 Dihydrocodeine,74 and Methadone79,80 did experience an increase 
in MVC risk. The results for both Codeine and Tramadol were mixed. Three studies 
investigated the effects of Codeine on the risk of MVC; two of these studies reported a 
statistically significant increase in MVC, 72,74 while one study did not.68 The study that did 
not report an association for the increased risk of MVC and Codeine may be because of 
sample size; 68 the study may not have had the statistical power to detect a difference. As for 
Tramadol, two studies investigated its effects and only one74 reported a statistically 
significant increase in MVC. This, too, may have been attributed to sample size. Out of 181 
collisions, only 20 people were found positive for Tramadol in the study conducted by Bachs 
et al.72
3.2.2 Anticonvulsants—Three studies investigated the effects of anticonvulsants, which 
included Carbamazepine,86 Phenytoin,63 and Valproate.73 As seen in Figure 3, none of these 
medications were associated with a statistically significant increase of MVC.63,73,86 Though 
not significant, Carbamazepine and Valproate were trending towards being protective against 
the risk of MVC.
3.2.3 Antidepressants—Antidepressant medications were the most studied class of drug. 
Twelve medications were investigated amongst three studies, which included 
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Amitriptyline,74,76 Cetirizine,74 Citalopram,74,76 Dosulepin,74,76 Escitalopram,76 
Fluoxetine,74,76 Lofepramine,74,76 Mirtazapine,76 Paroxetine,74,76 Sertraline,76 
Trazodone,74,76,81 and Venlafaxine.76 As seen in Figure 4, with the exception of one 
outcome for Dosulepin and two for Trazodone, virtually all of these medications were found 
to not be associated with a statistically significant increase of MVC. Though not significant, 
several of these medications were trending towards being protective against a MVC; this 
included Amitriptyline, Fluoxetine, Mirtazapine, Paroxetine, Sertraline, and Venlafaxine. In 
one study, Dosulepin was found protective76 against MVC while another study74 found no 
association. This may be attributed to the differences in study design or possibly the study 
population as the study that found Dosulepin protective was limited to older adult drivers.76 
All three studies investigated Trazodone and the findings for this medication were mixed. 
Two studies found Trazodone to not be statistically significant for the increased risk of 
MVC.74,76 Hansen found that both new (HR=2.15; 95% CI 1.83-2.51) and prevalent users 
(HR=1.47; 95 % CI 1.18-1.85) of Trazodone to be at increased risk of MVC.81 These 
differences may be attributed to the study population or possibly the study design.
3.2.4 Antihistamines—One study investigated the effects of nine antihistamines on the 
odds of MVC, which included Astemizole, Brompheniramine, Chlorphenamine, 
Desloratidine, Fexofenadine, Hydroxyzine, Levocitirizine, Loratadine, and Terfenadine.74 
As seen in Figure 5, only Levocitirizine was associated with an increased risk of MVC.74
3.2.5 Antihyperglycemics—Six studies investigated three antihyperglycemic 
medications which included Insulin, 66,71,75,84,85,88 Metformin, 88 and Sulfonylurea88 
(Figure 6). Of the six studies that reported outcome measures for Insulin, only two reported 
a statistically significant increase in MVC.66,75 The other four studies reported no 
statistically significant associations.71,84,85,88 This may be attributed to the adjustment of 
covariates. One study which included the odds of having any crash or a not-at-fault crash 
was adjusted for age, sex, race, and annual mileage,84 while another study was adjusted for 
age, gender, and days driven per week.85 Other studies were adjusted for age, sex, previous 
MVC, and place of residence,88 or unadjusted but stratified by the following ages: <25, 
25-44, 45-64, 65-74, and 75-84 years of age.71 Since two studies were not adjusted and the 
other studies were adjusted or stratified by age, it is possible that these two studies were 
statistically significant because they were left unadjusted.66,75 In addition, one study found 
that Metformin was not associated with an increased risk of crash, while Sulfonylurea was 
protective against MVC.88
3.2.6 Benzodiazepines—Nine benzodiazepines were investigated amongst seven studies 
which included Chlordiazepoxide,74 Diazepam,65,69,74,77,82 Flunitrazepam,70 Flurazepam,65 
Lorazepam,65 Nitrazepam,70,74 Oxazepam,65 Temazepam,74,81 and Triazolam65 (Figure 7). 
Chlordiazepoxide and Oxazepam were not found to be statistically significant for the 
increased risk of MVC.65,74 Flunitrazepam, Flurazepam, Lorazepam, Temazepam, and 
Triazolam were found to be statistically significant for an increased risk of MVC.65,70,74 The 
findings for Diazepam were slightly mixed. Of the five studies investigating the effects of 
Diazepam, four found a statistically significant increase in MVC65,69,74,82 while only one 
did not.77 Since the confidence intervals for one study was quite large, this estimate was 
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likely not precise.77 The findings were also mixed for Nitrazepam. One study found it to be 
associated with an increased risk of MVC70 while another did not.74 It should be noted that 
the study that did not report a statistically significant increase in MVC trended towards an 
increased risk.74 This discrepancy may have been attributed to different study designs.
3.2.7 Sleep Medications—Zolpidem and Zopiclone were the only two strictly sleep-
enhancing medications to be investigated (Figure 8). Five studies explored Zolpidem's 
effects,70,74,78,81,89 while six studies examined Zopiclone.70,74,77,78,82,89 Both medications 
appeared to be associated with an increased risk of MVC. Four70,78,81,89 of five studies 
found Zolpidem to be statistically significant for an increased risk of MVC. Two70,77 of six 
studies found Zopiclone to be statistically significant for an increased risk of MVC, while 
the other four were trending towards an increased risk, but not statistically 
significant.74,78,82,89
3.2.8 Other Medications—Eight medications could not be grouped into any of the other 
drug categories (Figure 9). These included Atenolol (i.e. a beta-blocker),74 Carisoprodol (i.e. 
a muscle relaxant),69 Estrogen (i.e. a hormone),85 Lithium (i.e. an antipsychotic),73,86 
Methyldopa (i.e. an antihypertensive)63 Propranolol (i.e. a beta-blocker),74 Salbutamol (i.e. 
an antispasmodic),69 and Warfarin (i.e. an anticoagulant).87 Of these medications, 
Carisoprodol was associated with a statistically significant increase in MVC.69 The findings 
for Lithium and Warfarin were mixed. One study reported an increased risk of MVC for 
Lithium86 while another reported no statistically significant association.73 This may have 
been attributed to differences in study design or the age of the population. As for Warfarin, 
one study found that Warfarin was initially protective against MVC for new users, but if 
taken for an extended period of time, no association was found.87 All other medications 
were not found to be statistically significant for the increased risk of MVC.
4. DISCUSSION
4.1 Findings
The principal finding of this study is that among the 53 specific medications investigated by 
the 27 studies included in this review, 15 medications (28.3%) were associated with an 
increased risk of motor vehicle collision. The medications that were associated with an 
increased risk of collision were: Buprenorphine, Codeine, Dihydrocodeine, Methadone, 
Tramadol, Levocitirizine, Diazepam, Flunitrazepam, Flurazepam, Lorazepam, Temazepam, 
Triazolam, Carisoprodol, Zolpidem, and Zopiclone. Two (3.8%) of the 53 medications, 
Sulfonylurea and Warfarin, may be protective against MVC. All other 36 medications 
(67.9%) were not significantly associated with MVC. The findings of this review illustrate 
that certain medications, even within the same class or drug category, may be more 
associated with crash risk than others.
These findings are consistent with the current literature. With the exception of Carisoprodol, 
Dihydrocodeine, and Tramadol, 12 of the 15 medications that were associated with 
increased MVC have also been studied in either driving simulations or actual driving 
assessments. Both types of studies use common measures to assess one's ability to safely 
navigate a vehicle; these measures include the ability to maintain position within the lane 
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[i.e. standard deviation of lateral position (SDLP)], tracking (i.e. following an object), 
missed instructions or directions, actual collisions with cars or objects, the ability to 
maintain constant speed, reactions or reaction time to stimuli, the ability to keep the vehicle 
on the road, steering wheel angle, divided attention (i.e. performing a task, such as 
acknowledging a sign or symbol, while driving), and gap acceptance (i.e. ability to judge 
distance between objects). There is evidence from both driving simulation and driving 
assessment studies that eight of these medications may also affect some aspects of driving 
ability; this includes Diazepam, Flunitrazepam, Flurazepam, Lorazepam, Temazepam, 
Triazolam, Zolpidem, and Zopiclone.
Diazepam, an anxiolytic, has been studied more extensively than any other of the 
medications. Six driving assessments90-95 and ten simulation studies 96-105 have investigated 
its effects on driving ability. The majority of studies have been randomized, double-blind, 
and cross-over by design. Participants in these studies have involved both genders of 
different age ranges. Professional drivers have also been used to study its effects.93 
Diazepam has been shown to negatively affect driving ability in virtually all the studies 
whether the source is an actual driving assessment or driving simulation. Collectively, 
Diazepam has affected nearly every aspect of driving ability including braking, SDLP, 
incidence of collisions, driver behavior, tracking, steering, car following, and reaction time, 
compared to placebo conditions.90-105
Flunitrazepam, a benzodiazepine, has been studied in one simulation106 and one driving 
assessment.107 In the simulation study, 16 healthy subjects underwent a double blind cross-
over study where they took Flunitrazepam the night before than completed the simulation 
the next morning to assess residual effects of the drug. Participants tended to speed when 
taking Flunitrazepam.106 In the driving assessment, 32 outpatients with sleep disorders 
received either 2 mg of Flunitrazepam or 20 mg of Temazepam daily for seven days and 
partook in a driving test on day one and day seven.107 Steering, lateral acceleration, and 
velocity were used to assess driving ability. Those taking Flunitrazepam experienced greater 
decreases in steering ability compared to Temazepam.107
Flurazepam, a benzodiazepine derivative, has been investigated in two driving 
assessments108,109 and two simulations.105,110 In a blinded, cross-over trial, 12 female 
volunteers received placebo or Flurazepam the night before and then drove a course the 
following morning. Under Flurazepam, participants incorrectly performed passable gaps.108 
In another double-blind, cross-over study, 16 patients treated for insomnia performed a 
75km driving assessment. When treated with Flurazepam, SDLP was decreased, but was 
more pronounced in female subjects during morning assessments.109 In a double-blind, 
cross-over simulation using 12 healthy volunteers, general reaction time to signals was 
impaired under Flurazepam compared to control periods.110 In another placebo-controlled, 
double-blind simulation using 54 healthy volunteers, executed tasks while driving were 
decreased in those taking Flurazepam compared to placebo periods.105
Lorazepam, a benzodiazepine, has been evaluated in seven driving assessments94,111-116 and 
one simulation.117 All of the studies were randomized, double-blind, and cross-over by 
design. Four of the driving assessments were limited to males,111,114-116 two to 
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females,112,113 and one to a group of clinically anxious and non-anxious participants of 
mixed gender.94 The simulation study encompassed healthy volunteers.117 Driving ability 
(i.e. SDLP, inappropriate line crossings, car handling, lane-keeping, speed, following 
distance, and tracking) was affected in all driving assessments and simulations.94,111-117
Temazepam, a benzodiazepine prescribed to treat short-term insomnia, has been evaluated in 
five driving assessments107,108,118-120 and one simulation study.121 All of the driving 
assessments and simulations were randomized, double-blind, and cross-over by design. The 
driving assessments used female volunteers in two studies,108,120 one used rotating shift 
workers,119 one used healthy volunteers,118 and one used insomniacs.107 The driving 
simulation used only female participants.121 Temazepam affected driving ability (i.e. 
participants hit more bollards) in only one study, but none of the others.108
Triazolam, a sedating benzodiazepine used to treat severe insomnia, has been studied in 
three driving assessments119,122,123 and three driving simulations.15,124,125 All three driving 
assessments were randomized, double-blind, and cross-over by design.119,122,123 Two of the 
studies used rotating shift workers119,123 while the third used healthy volunteers.122 In the 
two driving assessments using shift workers, Triazolam severely affected driving 
ability;119,123 driving performance was not as affected among the healthy volunteers.122 In 
the simulation studies, all three were similar in design and used commercial bus drivers as 
the study population.15,124,125 Driving ability (i.e. lane keeping, driving path, steering, 
braking, and SDLP) was affected in all of the simulation studies simulations.15,124,125
Zolpidem and Zopiclone, two sleep-promoting medications, were evaluated simultaneously 
in two driving assessments126,127 and four driving simulations.106,128-130 The two driving 
assessments were randomized, double-blind, and cross-over by design that used healthy 
participants of all age ranges.126,127 In both studies, Zopiclone and Zolpidem affected 
driving ability. In the simulation studies, all four were randomized, double-blind, and cross-
over by design; three studies used participants 55 years of age and older, 106,128,130 while the 
mean age in the fourth study was 38 years.129 Zopiclone affected driving ability in all four 
simulations; 106,128-130 Zolpidem affected driving ability in three simulations, 106,129,130 but 
not in the fourth.128 Zolpidem and Zopiclone were studied individually in three additional 
studies each. Zolpidem affected driving ability in all three studies, 121,131,132 while 
Zopiclone affected driving ability in two of the three studies.118,133,134
In addition to the eight medications described, four of the other 15 medications associated 
with increased risk of MVC have not been associated with affected driving ability during 
driving assessments or simulation studies; this includes Buprenorphine, Methadone, 
Levocitirizine, and Codeine. One driving simulation study investigated the effects of 
Buprenorphine and Methadone in a group of former heroin addicts whom were stabilized for 
at least three months and compared them to a group of healthy controls.135 SDLP, speed, 
steering wheel angle, and reaction time were used to assess driving ability. There was no 
difference in driving ability between the placebo group and those treated with either 
Buprenorphine or Methadone.135 Another study investigated the effects of Levocitirizine 
through an on-the-road assessment, which measured SDLP and speed to evaluate driving 
ability.136 No difference in performance was detected among those treated with 
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Levocitirizine and the control group.136 Codeine has been studied in three driving 
simulations.96,137,138 A randomized, double-blind, placebo-controlled, crossover study of 13 
healthy volunteers were administered therapeutic levels of Codeine and assessed on SDLP 
and time to collision under simulation. There were no differences between exposure and 
control periods.137 In another simulation study, 70, 16-22 year old professional drivers from 
the Finnish Army were randomized to various treatment and control groups and assessed on 
numerous factors during simulation.96 The only difference among the Codeine treated group 
was that they caused slightly more collisions.96 In another simulation study, which 
compared chronic pain users with Codeine, chronic pain users not using Codeine, and 
placebo group of healthy controls, participants were assessed on reaction time and missed 
reactions.138 No differences were detected in the Codeine treated group.138
While the remaining three medications, Carisoprodol, Dihydrocodeine, and Tramadol, have 
not been evaluated in driving assessments or driving simulations, their effects on 
psychomotor performance and/or cognition have been evaluated in laboratory settings. 
Carisoprodol, a muscle relaxant, can cause users to feel sedated, sluggish, and distracted, 
especially at high dosages.139,140 At therapeutic doses, Carisoprodol users often report 
feeling no effects of the medication even though their psychomotor functioning is decreased; 
this situation may cause users of this medication to underestimate its effects and partake in 
behaviors, such as driving, when they may be impaired.140 Dihydrocodeine, an opioid 
prescribed for mild to moderate pain, is known to cause dizziness and mild euphoria 
especially in new users,141 which may interfere with their ability to drive. Tramadol, an 
opioid for mild to moderate pain, has been shown to be fairly safe in respect to cognition and 
psychomotor function, though at higher doses, Tramadol has been linked to the worsening of 
balance.142 It should be noted that poor balance has been linked to higher incidences of 
MVC.143
4.1 Implications for research
From these findings, it is apparent that some medications that are associated with an 
increased risk of MVC do not appear correlated with decreased driving ability. Conversely, 
while the majority of the medications included in this review were not found to be 
statistically associated with increased risk of MVC, the inference that these medications are 
innocuous on one's ability to drive is not advised. There are several plausible reasons why 
the association between MVC and driving ability were not congruent with all medications 
presented in this review. First, this incongruence may be attributed to study design. The 27 
studies investigating the risk or odds of MVC were observational in nature, whereas the 
studies investigating driving ability were all randomized control trials (RCT) and therefore, 
experimental. The studies investigating driving ability were comprised of small sample sizes 
and were occasionally limited to certain age groups or genders. Therefore, the findings of 
the RCTs may not be generalizable to the entire population, which is a known limitation of 
this type of study design.144 In addition, the observational studies may not have been 
adjusted for key confounders whereas this would not have affected the RCTs results if 
participants were randomized properly.144 Also, most of the RCTs only investigated one or 
two aspects of driving ability. The act of driving is quite complex in nature. It is possible that 
other aspects of driving ability may not have been affected by the medication being 
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investigated. It is also plausible that even if driving ability is partially affected by a 
medication, some drivers may compensate their driving behaviors to avoid a potential 
collision, which is a known phenomenon.145-147 Second, epidemiological research 
investigating the associations between specific medications and MVC is lacking; this is 
evident by the number of studies included in this review. Some medications that have been 
studied via RCTs may not have been investigated observationally in larger populations. 
Third, many of the RCTs used healthy volunteers. This is problematic as disease-medication 
relationships are often difficult to distinguish. It is entirely possible that the disease in which 
the medication is prescribed is affecting an individual's ability to drive or their risk of MVC. 
It is also possible that driving ability is only affected for a short period of time and that an 
individual who takes a medication for an extended period of time develops a tolerance. This 
may not have been detected as the RCTs were often short in duration.
4.2 Implications for clinical practice
The findings of this review have several key clinical implications. First, the association 
between a specific medication and increased risk of MVC and decreased driving ability is 
not always clear. There are some specific medications that are most likely driver-impairing 
as both experimental and observational research has associated them with decreased driving 
ability and increased risk of MVC, respectively. These include Diazepam, Flunitrazepam, 
Flurazepam, Lorazepam, Temazepam, Triazolam, Zolpidem, and Zopiclone. For other 
medications, such as Buprenorphine, Codeine, Methadone, and Levocitirizine, there appears 
to be an association between them and increased risk of MVC, but not driving ability. As for 
Tramadol, Carisoprodol, and Dihydrocodeine, they appear to be associated with increased 
risk of MVC, but have not been evaluated in driving assessments or simulations. Secondly, 
some specific medications belonging to the same category or class may be more detrimental 
than others. For example, among the ‘Other Medications” included in this review, 
Carisoprodol had a strong association with MVC while the other medications in this 
category did not. Thirdly, some of these medications are widely prescribed. For example, 
Buprenorphine was the 39th most sold drug in the United States during the fourth quarter of 
2013.148 Therefore, careful consideration of the patient and their lifestyle must be given 
when these medications are prescribed. Possible alternatives within a drug category or class 
should be considered for patients that frequently drive as certain medications may be more 
driver-impairing than others. Education efforts are needed to ensure that patients are aware 
that certain medications may increase their risk of MVC.
4.3 Strengths and limitations of this review
The strengths of this review are that over 50 years of data among fourteen different 
databases were searched for potential studies. This review also included relevant ‘grey 
literature’ as evidenced by the inclusion of three doctoral dissertations and one conference 
paper. Despite its strengths, this review is not without its limitations. For example, 
publication bias is a known limitation of systematic reviews.144 It is also possible that some 
studies may have been missed despite two authors independently reviewing studies for 
inclusion. As much of the DUID research arises from Europe, 59 it is likely that several 
studies were not included or missed as they were not available in the English language, a 
requirement of the a priori inclusion criteria. In some instances, only abstracts and not 
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complete studies could be retrieved, especially with reports or conference papers that were 
dated. Also, some studies were adjusted for potential confounders, while others were crude 
estimates. The findings of this review also indicate that future research opportunities in this 
area of study are plentiful. Future research could entail, 1) RCTs of medications found to be 
associated with increased risk of MVC that were never evaluated in a driving assessment or 
simulation, 2) epidemiological studies investigating the effects of other medications or new 
medications that may be driver-impairing, 3) investigating different methods of measuring 
driving ability in simulations and actual assessments, and 4) pursuing patient or clinician 
educational efforts to raise awareness about the possible effects of specific medications on 
MVC or affected driving ability.
4.4 Conclusions
This systematic review sought to determine which specific medications were associated with 
increased risk of motor vehicle collision among licensed drivers. While the majority of 
medications investigated were found to not be significantly associated with increased MVC, 
several medications were associated with such risks. It was also determined that some 
medications may be more driver-impairing than others. These findings pose numerous 
clinical implications. Due to the increasing public health and traffic safety concerns 
regarding driving under the influence of drugs, future research in this area of study is worthy 
of investigation as the associations between specific medication use and the increased risk of 
motor vehicle collision or affected driving ability are complex and not always lucid.
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Of the 27 studies included in this review, 53 medications were investigated
15 medications (28.3%) were associated with motor vehicle collision risk
As these drugs are widely prescribed, clinical and research implications exist
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Flow chart for the selection of studies.*, studies could have been excluded for multiple 
reasons
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Odds or risk ratios with corresponding 95% confidence intervals from included studies that 
investigated the association between specific analgesic medications and MVC. Estimates by 
Foley et al83 were adjusted for age and gender; all other estimates presented are unadjusted.
Rudisill et al. Page 25














Odds or risk ratios with corresponding 95% confidence intervals from included studies that 
investigated the association between specific anticonvulsant medications and MVC. The 
study by Etminan et al.86 was adjusted for age, sex, residence, previous MVC, chronic 
disease score, and exposure to antidepressants, antiepileptic, benzodiazepines, 
antipsychotics, antimigraine, muscle relaxants, and/or narcotic analgesics. All other 
estimates are unadjusted.
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Odds or risk ratios with corresponding 95% confidence intervals from included studies that 
investigated the association between specific antidepressant medications and MVC. The 
study by Hansen81 provided two estimates. The first estimate (81a) corresponds to new users 
of Trazodone while the second (81b) corresponds to prevalent users of Trazodone.
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Odds or risk ratios with corresponding 95% confidence intervals from included studies that 
investigated the association between specific antihistamine medications and MVC
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Odds or risk ratios with corresponding 95% confidence intervals from included studies that 
investigated the association between specific antihyperglycemic medications and MVC. The 
study by Lonnen et al71 provided five estimates of risk (71a-e). These correspond to the risk 
of MVC for the following age groups respectively, <25, 25-44, 45-64, 65-74, and 75-84 
years of age. The study by Mcgwin et al84 provided two estimates of risk (84a-b), which 
correspond with the odds of having any crash or a not-at-fault crash, respectively. The study 
by Mcgwin et al84 was adjusted for age, sex, and annual miles driven. The study by Sims et 
al85 was adjusted for sex, age, and days driven per week. The study by Hemmelgarn et al.88 
was adjusted for age, gender, previous MVC, and place of residence. All other estimates are 
unadjusted.
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Odds or risk ratios with corresponding 95% confidence intervals from included studies that 
investigated the association between specific benzodiazepine medications and MVC. 
Hansen81 provided two estimates of risk (81a-b) which correspond to new and prevalent 
users of Temazepam, respectively.
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Odds or risk ratios with corresponding 95% confidence intervals from included studies that 
investigated the association between specific sleep-promoting medications and MVC. 
Hansen81 provided two estimates of risk (81a-b) which correspond to new and prevalent 
users of Zolpidem, respectively. The estimates provided by Yang et al.89 were adjusted for 
concomitant use of the following medications: Zolpidem, Zopiclone, long and short acting 
benzodiazepines, antihistamines, anticonvulsants, antidepressants, other sedatives/hypnotics, 
other psychoactive drugs, muscle relaxants, and opioid analgesics. All other estimates are 
unadjusted.
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Odds or risk ratios with corresponding 95% confidence intervals from included studies that 
investigated the association between MVC and specific medications that could not be 
grouped into the other drug categories. Delaney et al87 provided two estimates of risk (87a-
b) which correspond to both new and prevalent users, respectively, of Warfarin. The study by 
Sims et al.85 was adjusted for sex, age, and days driven per week. The study by Etminan et 
al.86 was adjusted for age, sex, residence, previous MVC, chronic disease score, and 
exposure to antidepressants, antiepileptic, benzodiazepines, antipsychotics, antimigraine, 
muscle relaxants, and/or narcotic analgesics. The study by Delaney et al.87 was adjusted for 
cardiac or stroke events within the past year and the following drug classes in the previous 
60 days: antidepressants, anti-epileptics, benzodiazepines, antipsychotics, anti-migraine, 
narcotic analgesics, muscle relaxants. All other estimates are unadjusted.
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Table 1
Characteristics of included studies that investigated the risk or odds of motor vehicle collision and specific 
medication (s)
Author Year Country Study Design Outcome Measure Population
a
 Characteristics Medications Investigated Source
b Quality Score
Nelson63 1992 U.S. Case-Control Odds Ratio 30-65 yrs, females Methyldopa, Phenytoin R 5/5
Koepsell et al.64 1994 U.S. Case-Control Odds Ratio ≥65 yrs, both genders Insulin R 5/5
Foley et al.83 1995 U.S. Cohort Relative Risk ≥65 yrs, both genders Aspirin S 5/5
Neutel65 1998 Canada Case-Control Odds Ratio ≥20 yrs, both genders Diazepam, Flurazepam, Lorazepam, 
Oxazepam, Triazolam
R 4/5
McGwin et al.84 2000 U.S. Case-Control Odds Ratio ≥65 yrs, both genders Insulin S 5/5
Sims et al.85 2000 U.S. Cohort Relative Risk ≥55 yrs, both genders Estrogen, Insulin S 5/5
Cui66 2001 Canada Case-Control Odds Ratio ≥65.5 yrs, both genders Insulin R 5/5
Mura et al.67 2003 France Case-Control Odds Ratio ≥18 yrs, both genders Morphine L 4/5
Etminan et al.86 2004 Canada Case-Control Odds Ratio 67-84 yrs, both genders Carbamazepine, Lithium R 5/5
Delaney et al.87 2006 Canada Case-Control Odds Ratio 67-84 yrs, both genders Warfarin R 5/5
Hemmelgarn et al.88 2006 Canada Case-Control Odds Ratio 67-84 yrs, both genders Insulin, Metformin, Sulfonylurea R 5/5
Mathijssen et al.68 2006 Netherlands Case-Control Odds Ratio ≥18 yrs, both genders Codeine L 4/5
Bramness et al.69 2007 Norway Cohort Relative Risk 18-69 yrs, both genders Carisoprodol, Diazepam, Salbutamol R 5/5
Gustavsen et al.70 2008 Norway Cohort Relative Risk 18-69 yrs, both genders Flunitrazepam, Nitrazepam, 
Zolpidem, Zopiclone
R 5/5
Lonnen et al.71 2008 England Cohort Relative Risk ≥15 yrs, both genders Insulin R 4/5
Bachs et al.72 2009 Norway Cohort Relative Risk 18-70 yrs, both genders Codeine, Tramadol R 5/5
Bramness et al.73 2009 Norway Cohort Relative Risk 18-69 yrs, both genders Lithium, Valproate R 4/5








Lofepramine, Loratadine, Morphine, 
Nitrazepam, Paroxetine, 
Propranolol, Temazepam, 
Terfendine, Tramadol, Trazodone, 
Zopiclone, Zolpidem
R 5/5
Skurtveit et al.75 2009 Norway Cohort Relative Risk 18-69 yrs, both genders Insulin R 5/5
Coupland et al.76 2011 England Cohort Relative Risk ≥65 yrs, both genders Amitiptyline, Citalopram, 
Dosulepin, Escitalopram, 
Fluoxetine, Lofepramine, 
Mirtazapine, Paroxetine, Sertraline, 
Trazodone, Venlafaxine
R 5/5
Gjerde et al.77 2011 Norway Case-Control Odds Ratio Both genders Diazepam, Zopiclone L 4/5
Orriols et al.78 2011 France Case-Control Odds Ratio Both genders Zopiclone, Zolpidem R 5/5
Yang et al.89 2011 Taiwan Case-Crossover Odds Ratio ≥18 yrs, both genders Zopiclone, Zolpidem R 5/5
Bramness et al.79 2012 Norway Cohort Relative Risk 18-69 yrs, both genders Methadone R 5/5
Corsenac et al.80 2012 France Case-Control Odds Ratio Both genders Buprenorphine, Methadone R 5/5
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Author Year Country Study Design Outcome Measure Population
a
 Characteristics Medications Investigated Source
b Quality Score
Hansen.81 2012 U.S. Cohort Relative Risk 21-79 yrs, both genders Temazepam, Trazodone, Zolpidem R 5/5
Gjerde et al.82 2013 Norway Case-Control Odds Ratio Both genders Diazepam, Zopiclone L 4/5
a
Yrs=years; if age is not specified, the population came from a registry of drivers in the country of origin
b
Source indicates how prescription drug information was collected in each of the studies. R=medical/dispensing/insurance records or registry; 
L=laboratory test, S=self-report
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